Related Experiment Video
Updated: Mar 7, 2026
Live Imaging of Nicotine Induced Calcium Signaling and Neurotransmitter Release Along Ventral Hippocampal Axons
Published on: June 24, 2015
α7 Nicotinic Acetylcholine Receptor as a Therapeutic Target in Central Nervous System Diseases: Prospects and
Zhe-Qi Xu1, Yi-Xin Xu2, Zhu-Qing Wang1
1Department of Pharmacy, Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Introduction:
The α7 nicotinic acetylcholine receptor (α7nAChR), a transmitter-gated ion channel, is normally activated by the endogenous neurotransmitter acetylcholine (ACh). Its activation triggers a distinctive cholinergic anti-inflammatory pathway, leading to anti-inflammatory effects in the central nervous system (CNS). This unique pharmacological property has positioned α7nAChR as a promising therapeutic target for multiple CNS disorders. This review delineates α7nAChR's multifaceted roles in CNS pathophysiology, appraises current clinical trial progress of its modulators, and elucidates key challenges and future directions for the development of next-generation therapeutics targeting α7nAChR.
Methods:
Studies demonstrate that activation of α7nAChR represents a promising therapeutic strategy for diverse CNS disorders, including neurodegenerative, cerebrovascular, and neurodevelopmental diseases.
Results:
Studies demonstrate that activation of the α7nAChR is a promising therapeutic strategy for diverse CNS diseases, including neurodegenerative, cerebrovascular, and neurodevelopmental diseases.
Discussion:
This review highlights the core therapeutic value of α7nAChR in CNS disorders while identifying bottlenecks in its research and development. On one hand, preclinical studies show that α7nAChR's anti-inflammatory and neuroprotective effects support its potential as a therapeutic target. On the other hand, clinical trial data-including limited efficacy and dose-limiting cardiovascular adverse effects-reveal a persistent translational gap from preclinical to clinical.
Conclusion:
Although α7nAChR agonists hold considerable therapeutic potential, substantial challenges remain in clinical translation. Major hurdles include: (1) the inherent complexity of the CNS microenvironment, which affects receptor pharmacology; (2) insufficient subtype selectivity, leading to off-target effects; and (3) a scarcity of clinically efficacious compounds. Addressing these limitations is crucial for the successful development of α7nAChR-targeted therapies.
More Related Videos
10:48Probing Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices via Laser Flash Photolysis of Photoactivatable Nicotine
Published on: January 25, 2019
10:04Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices
Published on: October 29, 2012
Related Concept Videos
01:15Cholinergic Receptors: Nicotinic
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
01:25Cholinergic Receptors: Muscarinic
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...